Pharmaceutical Business Products

Our dream is to bring highly original drugs to patients by taking untraveled paths. This is why Otsuka Pharmaceutical passionately embraces the challenge of developing path-breaking products.

Global Therapeutic Drugs
List

  • V2-receptor antagonistSamsca
  • Antiplatelet agentPletaal
  • AntipsychoticABILIFY
  • AntipsychoticAbilify Maintena
  • Antiepileptic drugE Keppra
  • Dopaminergic antiparkinsonian drug
    Drug for restless legs syndrome
    Neupro Patch
  • Conditioning agent prior to allogenic
    hematopoietic progenitor cell transplantation
    Busulfex
  • Anti-cancerSPRYCEL
  • Anti-gastritis & anti-gastric ulcer agentMucosta
  • Therapeutic agent for dry eyeMucosta ophthalmic suspension
  • V2-receptor antagonistPhysuline
  • BronchodilatorMeptin
  • BronchodilatorUNIPHYL LA
  • Levocarnitine preparationL-Cartin
  • Anti-cancer (Renal Cell Carcinoma)OIF
  • Oral nutrient for liver failureAminoleban EN
  • β-blockerMikelan, Mikelan LA
  • Hyperlipidemia agentLorelco
  • Hyperlipidemia agent, climacteric disturbance
    and irritable bowel syndrome
    Hi-z
  • β-blocker ophthalmic solutionMikelan ophthalmic solution,
    Mikelan LA ophthalmic solution
  • Broad-spectrum antibacterial ophthalmic
    solution
    OZEX ophthalmic solution
  • Intraocular irrigating solutionOPEGUARD NEO KIT
  • Topical new quinolone antibacterial agentAcuatim
  • Anti-mycotic agentPalavale
  • Anti-keratosis agentUrepearl

Diagnostics & Medical
Equipment List

  • Diagnostic agent for H.pylori infectionUBIT
  • H.pylori antibody detection kitRAPIRUN H.pylori antibody STICK
  • S. pneumoniae detection kitRAPIRUN S. pneumoniae
  • Rapid test for the detection of influenza
    A and B virus antigens
    Quick Navi-Flu
  • Rapid test for the detection of influenza
    A and B virus and respiratory syncytial
    virus antigens
    Quick Navi-Flu+RSV
  • Rapid test for the detection of adenovirus
    antigens
    Quick Navi-Adeno
  • Rapid test for the detection of respiratory
    syncytial virus antigens
    Quick Navi-RSV
  • Rapid test for the detection of norovirus
    antigens
    Quick Navi-Noro2
  • Series of urinalysis test strips for compounds /
    metabolites
    Uropaper "Eiken"
  • Reagents for measurement of Wilms'
    tumor-1 gene
    (WT1) mRNAWT1 mRNA Assay
    Kit "Otsuka"
  • RIA kit for sialyl Lex-i antigen in serumSLX "OTSUKA"
  • Infrared spectrophotometer for
    the measurement of 13CO2level in the breath
    POCone
  • Fingertip blood samplerFingraph

The contents of this page are governed by the laws of Japan.

V2-receptor antagonist
Samsca

Samsca is a free water clearance drug (aquaretic) with a completely novel mechanism of action; it promotes excretion from the body of water only without directly affecting the excretion of electrolytes. It does this by inhibiting the antidiuretic hormone vasopressin. In Japan it has been sold since 2010 with an indication for water retention in cardiac failure in which loop and other diuretics have an inadequate effect. Outside Japan it has been approved for different indications and is sold in 14 countries in North America, Europe, and Asia.

The information in the product description is current as of March 2013.

close

Antiplatelet agent
Pletaal

Pletaal is an antiplatelet agent with platelet aggregation inhibitor and peripheral vasodilator effects. In Japan it was launched in 1988 with an indication for improvement of ischemic symptoms including ulcers, pain, and coldness associated with chronic arterial obstruction and was approved in 2003 for an additional indication for prevention of recurrent cerebral infarction (excluding cardiogenic cerebral embolism). In 2010, Pletaal OD tablets were released in Japan.

The information in the product description is current as of March 2013.

close

Antipsychotic
ABILIFY

ABILIFY is an antipsychotic with the world’s first dopamine D2 receptor partial agonist action, which was researched and developed by Otsuka Pharmaceutical. In Japan it was launched in 2006 for the treatment of schizophrenia and in 2012 obtained an additional indication for improvement of manic symptoms of bipolar disorder. Following its launch in the U.S. in 2002, ABILIFY has been approved in more than 70 countries worldwide.

The information in the product description is current as of March 2013.

close

Antipsychotic
Abilify Maintena

Abilify Maintena is a prolonged-release injection (once-monthly administration) of the antipsychotic ABILIFY with the world’s first dopamine D2 receptor partial agonist action, which was researched and developed by Otsuka Pharmaceutical. In 2013, it was approved and launched in the U.S. for the treatment of schizophrenia.

The information in the product description is current as of March 2013.

close

Antiepileptic drug
E Keppra

E Keppra, developed by the Belgian company UCB, is an antiepileptic drug with a novel mechanism of action that binds to synaptic vesicle proteins in the brain. Since being approved as a combination therapy against partial seizures in adult epilepsy patients in the U.S. in 1999 the drug has been sold by UCB in more than 90 countries and regions worldwide. In Japan, Otsuka Pharmaceutical has been co-marketing E Keppra with UCB as a treatment for partial seizures in adult epilepsy patients since September 2010.

The information in the product description is current as of March 2013.

close

Dopaminergic antiparkinsonian drug
Drug for restless legs syndrome

Neupro Patch

Neupro Patch is the world’s only transdermal dopamine agonist. Otsuka Pharmaceutical obtained development and marketing rights in Japan from the Belgian company UCB. In Japan, it has been sold since 2013 for the treatment of Parkinson’s disease and restless legs syndrome. Outside Japan UCB markets the product in 35 countries under the brand name Neupro.

The information in the product description is current as of March 2013.

close

Conditioning agent prior to allogenic
hematopoietic progenitor cell transplantation

Busulfex

Busulfex is an intravenous injection of busulfan (generic name), an anticancer agent that inhibits DNA synthesis and cell division. It is the only drug approved by the U.S. Food and Drug Administration (FDA) as a conditioning agent prior to allogenic hematopoietic progenitor cell transplantation (e.g. bone marrow transplantation) in blood cancer patients. It has been accepted globally as a standard treatment supporting medical transplantation and is sold in more than 50 countries worldwide.

The information in the product description is current as of March 2013.

close

Anti-cancer
SPRYCEL

SPRYCEL, an oral drug discovered and developed by Bristol-Myers Squibb, is a second-generation tyrosine kinase inhibitor that inhibits Bcr-Abl tyrosine kinase, which is the cause of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). In 2006, it was approved in the U.S. and Europe and has been approved in more than 60 countries worldwide. Otsuka Pharmaceutical has been promoting the product in Japan since 2009.

The information in the product description is current as of March 2013.

close

Anti-gastritis & anti-gastric ulcer agent
Mucosta

Mucosta is an anti-gastritis and anti-gastric ulcer agent with an action that protects the gastric mucosa in addition to suppressing free radicals and inflammation in the stomach. It is widely used as a drug that controls gastric mucosa injury triggered by various causes such as use of painkillers and the effects of Helicobacter pylori. It was launched in Japan in 1990 and is now sold in 10 countries and regions worldwide.

The information in the product description is current as of March 2013.

close

Therapeutic agent for dry eye
Mucosta ophthalmic suspension

Mucosta ophthalmic suspension is a novel dry eye treatment with action that repairs corneal and conjunctival damage by promoting the production of mucin in the cornea and conjunctiva. It is used by dry eye patients with corneal and conjunctival epithelial cell damage associated with lacrimal disorders. It was launched in Japan in January 2012 as a unit-dose (single-dose) formulation that does not contain preservatives.

The information in the product description is current as of March 2013.

close

Diagnostic agent for H.pylori infection
UBIT

UBIT is a diagnostic agent that can detect the presence of Helicobacter pylori in the stomach. It was launched in Japan in 1999. Outside Japan it is sold in countries including South Korea, Singapore, Malaysia, Vietnam, and Thailand. A product called BreathTek, which uses the same mechanism, is sold in the U.S.

The information in the product description is current as of March 2013.

close